Induction and Maintenance of Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients: a Retrospective and Prospective Nationwide Study in Switzerland

Who is this study for? Patients with Liver Disease, Immunosuppression
What treatments are being studied? Vaccination with VZV Vaccine
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY

Varicella is a vaccine-preventable disease, which can be severe in immunosuppressed children. Currently, the (live) vaccine is not recommended in pediatric orthotopic liver transplant recipients. Furthermore, protection due to naturally acquired immunity to VZV or post-immunization isn't well described in this population.The questions asked are: * What is the influence of the immunosuppression required after orthotopic liver transplantation (OLT) on the maintenance of VZV-specific immunity elicited by wild-type varicella infection before OLT transplantation? * What is the influence of the immunosuppression required after OLT on VZV-specific immunity elicited by varicella immunization before OLT transplantation? * What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the induction of VZV-specific B and T cell responses elicited by VZV vaccination after OLT transplantation? * What is the influence of the residual immunosuppression at ≥ 12 months after OLT transplantation on the persistence / waning of B and T cell responses elicited by VZV vaccination?

Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:

• Children either awaiting or recipients of a liver transplantation followed at the Children's Hospital of Geneva, Switzerland

• If vaccination offered: \> 12 months of age

Locations
Other Locations
Switzerland
Children's Hospital of Geneva (HUG)
RECRUITING
Geneva
Contact Information
Primary
Klara M Posfay-Barbe, MD, MS
Klara.PosfayBarbe@hcuge.ch
+41 22 372 5462
Backup
Valerie McLin, MD
Valerie.McLin@hcuge.ch
+41 22 3723311
Time Frame
Start Date: 2007-06
Estimated Completion Date: 2025-12
Participants
Target number of participants: 80
Treatments
Other: Varicella vaccine
2-3 doses of Varicella vaccine to seronegative patients two months apart
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Geneva

This content was sourced from clinicaltrials.gov